
    
      The objective of this study is to evaluate the tolerability and safety of TAK-385 in hormone
      treatment-naive participants with non-metastatic prostate cancer. This study consists of two
      parts: Part A, multiple dose-rising (MRD) phase and Part B, an expansion phase.
    
  